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Abstract
Correct classiﬁcation of death causes is an important component of transplant trials.
We aimed to develop and validate a system to classify causes of death in hematopoietic stem cell (HSCT) and solid organ (SOT)
transplant recipients.
Case record forms (CRF) of fatal cases were completed, including investigator-designated cause of death. Deaths occurring in
2010 to 2013 were used for derivation; and were validated by deaths occurring in 2013 to 2015. Underlying cause of death (referred
to as recorded underlying cause) was determined through a central adjudication process involving 2 external reviewers, and
subsequently compared with the Danish National Death Cause Registry.
Three hundred eighty-eight recipients died 2010 to 2015 (196 [51%] SOT and 192 [49%] HSCT). The main recorded underlying
causes of death among SOT and HSCTwere classiﬁed as cancer (20%, 48%), graft rejection/failure/graft-versus-host-disease (35%,
28%), and infections (20%, 11%). Kappa between the investigator-designated and the recorded underlying cause of death was 0.74
(95% CI 0.69–0.80) in derivation and comparable in the validation cohort. Death causes were concordant with the Danish National
Death Cause Registry in 37.2% (95% CI 31.5–42.9) and 38.4% (95% CI 28.8–48.0) in the derivation and validation cohorts,
respectively.
We developed and validated a method to systematically and reliably classify the underlying cause of death among transplant
recipients. There was a high degree of discordance between this classiﬁcation and that in the Danish National Death Cause Registry.
Abbreviations: aOR = adjusted odds ratio, CI = conﬁdence interval, CRF = case record form, DNDCR = Danish National Death
Cause Registry, GvHD = Graft versus host disease, HIV = human immunodeﬁciency virus, HSCT = hematopoietic stem cell
transplantation, ICD = International Classiﬁcation of Diseases, IQR = inter-quartile range, MATCH =Management of Post-Transplant
Infections in Collaborating Hospitals, SOT = solid organ transplantation.
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1. Introduction
During the past few decades, death following transplantation has
decreased markedly. This is mainly due to better graft preservation,
progress in surgical treatment, enhanced immunosuppressive
regimens, and introduction of new preventive strategies towards
infections. However, despite decreasing mortality following trans-
plantation, the death rates of transplant recipients still exceed those
observed in the age-matched general population.[1] This is mainly
due to considerable comorbidities such as cardiovascular disease,[1–
3] opportunistic infections due to immunosuppression,[2,4,5] or
increased risk of de novo and secondary cancer following
transplantation. While infections are important, they lead to death
in substantially fewer cases than in the past.[6] This improvement in
management strategies has allowed for more intensive and effective
immunosuppressive treatment and had a major positive impact on
the short-term mortality after transplantation.[7]
Correct classiﬁcation of underlying causes of death is an
important component of conducting research aimed to improve
quality of care in transplant medicine. Furthermore, patterns of
underlying causes of deaths may change in a ﬁeld with continuing
introduction of novel drugs with uncertain long term efﬁciency.[8]
Hence, temporal surveillance of the patterns of underlying causes of
deaths is required to detect potential emerging challenges in this
vulnerable patient population. Themerits of a uniform classiﬁcation
system, applicable to different countries, clinical settings, and
irrespective of treatment protocols and place of death appear to be
clear. However, such a classiﬁcation system does not exist currently.
We therefore aimed to develop and validate a system to classify
underlying causes of death in hematopoietic stem cell (HSCT)
and solid organ (SOT) transplant recipients. Furthermore, we
sought to evaluate if there were any speciﬁc characteristics that
can facilitate the determination of the cause of death.
2. Materials and methods
2.1. Patients
All the included patients of this study were registered in the
Management of Post-Transplant Infections in Collaborating
Hospitals (MATCH) cohort.[9] The MATCH program was
introduced at Rigshospitalet, a large tertiary transplant center in
Copenhagen, Denmark in 2011, with the aim to reduce the risk of
severe viral diseases in transplant recipients. MATCH constitutes
a platform for collaboration between the transplantation units
and the Department of Infectious Diseases, and the associated
database contains data on a large cohort of consecutive
transplant recipients of solid organ and hematopoietic stem cell
transplantation. All recipients transplanted with a liver or lung
transplants in all of Denmark since 2004 were enrolled into
MATCH and furthermore all heart, kidney, and hematopoietic
stem cell transplantation in the eastern region of Denmark were
enrolled. Eligible patients consisted of children or adults who had
received a solid organ or hematopoietic stem cell transplantation
between Jan 1st, 2004 and Dec 31st, 2014, and who had died
between Jan 1st, 2010 and Dec 12th, 2015. As the electronic
medical system at our hospital was introduced in 2010, medical
records prior to 2010 were either not included in the electronic
medical system or were less complete. We, therefore, excluded
patients who died prior to 2010.
2.2. Derivation of the classiﬁcation systems
An expert panel consisting of specialists within the transplant
ﬁeld was convened to establish a consensus-based classiﬁcation
system. All specialists were specialized doctors and/or professors
within the different included transplant ﬁelds. Based on
contribution from the participants a standardized case record
form (CRF) (Supplemental digital content 1, http://links.lww.
com/MD/C345), an online review form (Supplemental digital
content 2, http://links.lww.com/MD/C345), a list with pre-
deﬁned categories of death (Supplemental digital content 3,
http://links.lww.com/MD/C345), and an algorithm for deﬁning
the cause of death was proposed (Supplemental digital content 3,
http://links.lww.com/MD/C345).
The purpose of the classiﬁcation system was to attribute 1
immediate, up to 5 contributing and 1 underlying cause of death
to the speciﬁc pre-deﬁned categories (14 categories in total) and
to provide a certainty level to each cause of death; deﬁnite
indicated a certainty of 95% to 100%; likely 80% to 95%; and
possible 50% to 80%. The degrees of certainty were determined
at the discretion of the external reviewers and were based on to
which extent available objective parameters (such as documen-
tation with biopsies or imaging) could prove the cause of death.
Once the CRF and classiﬁcation system was drafted, a panel
consisting of 2 transplant specialists reviewed 5 randomly
selected cases to reﬁne the system further.
2.3. Assessment process
After the classiﬁcation system was developed, hospital medical
records were retrospectively reviewed by trained investigators
with medical backgrounds, for example, non-specialized physi-
cians and research associates, to extract clinical information onto
the standardized CRF. The investigators also proposed the cause
of death in the CRF (investigator-designated cause of death). The
CRFs then went through an assessment process as illustrated in
Fig. 1. The CRF’s were divided among 7 external reviewer teams.
The teams consisted of 1 physician specialized within the patients’
transplant type and another specialized within another ﬁeld. The
2 reviewers in each team then reviewed the CRF and
independently determined the cause of death. In case of
disagreement regarding the recorded underlying cause of death,
an agreement was sought through an independent discussion
between 2 reviewers blinded to each other. If the disagreement
persisted, the underlying cause of death was determined by an
expert panel consisting of 1 Professor of Internal Medicine and 1
Professor of Surgery.
2.4. Validation of the derived classiﬁcation system
The cohort was divided in 2 groups; the classiﬁcation system was
derived from patients who had died between Jan 1st, 2010 and
Oct 31st, 2013, and validated on those who died betweenNov 1st,
2013 and Dec 12th, 2015.
2.5. Comparison of cause of death with the Danish
National Death Cause Registry (DNDCR)
The recorded underlying cause of death of patients in both the
derivation and validation cohorts were compared with the
reported cause of listed in the Danish National Death Cause
Registry. The DNDCR retrieves information from death
certiﬁcates and codes cause of death according to International
Classiﬁcation of Diseases 10 (ICD-10).[10] For comparison, the
14 speciﬁc categories included in our classiﬁcation algorithm
were assigned a corresponding ICD-10 (Supplemental digital
content 4, http://links.lww.com/MD/C345).
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2.6. Statistics
Agreement between the investigator-designated and recorded
underlying causes of death, as well as the agreement between the
2 external reviewers was compared. Proportion of agreement was
calculated and inter-rater agreement was assessed using Cohen
Kappa statistics. Strength of agreement was deﬁned as slight
(0.00–0.20), fair (0.21–0.40), moderate (0.41–0.60), substantial
(0.61–0.80), or almost perfect (0.81–1.00).[11]
Univariate logistics regression models were used to identify
characteristics (information retrieved from the CRF) associated
with agreement of the underlying cause of death. Agreement was
assessed between the investigator-designated and recorded
underlying cause of death (decided by the experts after
adjudication) and independent agreement (before adjudication)
between the 2 external reviewers. A multivariable model was
constructed based on variables with P< .1 in univariate analyses.
The P value of <.05 was considered as signiﬁcant difference.
Characteristics independently associated with agreement
between the investigator-designated and recorded underlying
cause of death identiﬁed in the multivariate logistic regression
model with a P-value <.1, were subsequently evaluated in
different combinations by Cohen Kappa statistics in order to
determine speciﬁc patterns of characteristics that led to good
agreement of underlying cause of death. These patterns were
identiﬁed based on the derivation data, prior to analysis of the
validation data. Following the identiﬁcation of these speciﬁc
patterns in the derivation cohort, their reproducibility was
subsequently tested in the validation cohort.
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS) version 22 (IBM, New
York, NY).
2.7. Approvals
The research is conducted after approval of the National Data
Protection Agency (2012-58-0004, RH-2015-67, with I-Suite
number: 03787).
3. Results
3.1. Patient characteristics and recorded underlying cause
of death
A total of 388 patients died between Jan 1st, 2010 and Dec 12th,
2015; of these, 286 (74%) occurred in the derivation and 102
(26%) in the validation cohort. The 2 cohorts were similar in
terms of baseline characteristics (Table 1). A slightly higher
proportion of recipients had a concomitant infection at time of
death in the derivation cohort, compared with the validation
cohort (74% vs 68%, P= .05). Conversely, the proportion with
prior cerebrovascular disease and ABO compatibility (e.g A, B, O
Figure 1. Assessment process of the CLASS project. Case record forms (CRF) were completed by trained investigators at the Central Coordinating Center. CRFs
include clinical information around the time of death. Furthermore, the investigators proposed a cause of death (investigator-designated cause of death). The
completed CRF’s were then reviewed by 2 external reviewers who were blinded to each other and who each independently determined cause of death using the
cause of death algorithm (Supplemental digital content 3, http://links.lww.com/MD/C345). The 2 external reviewers consisted of 1 specialist within the transplant
ﬁeld and 1within another ﬁeld, including infectious disease specialists. Where the 2 reviewers agreed on the underlying cause of death (independent agreement), the
case would be ﬁnalized and underlying cause of death recorded (recorded underlying cause of death). In case of disagreement, the underlying cause of death were
resolved by an online adjudication process where the reviewers were able to see each other’s recordings and correspond anonymously (Adjudicated agreement).
Where the 2 external reviewers could not reach consensus on the underlying cause of death, the case would be discussed by 2 other randomly selected experts to
determine the underlying cause of death.
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Table 1
Characteristics of patients at time of death in the derivation and validation cohorts.
Characteristics All Derivation cohort Validation cohort P-value
Total, N (%) 388 (100) 286 (74) 102 (26)
Transplant type, N (%) .34
HSCT 192 (49) 145 (51) 47 (46)
Lung 80 (21) 60 (21) 20 (19.5)
Kidney 53 (14) 33 (12) 20 (19.5)
Liver 51 (13) 38 (13) 13 (13)
Heart 12 (3) 10 (3) 2 (2)
Age (y); median (IQR) 55 (42–65) 55 (42–63) 56 (43–65) .96
Female; N (%) 163 (42) 123 (43) 40 (39) .51
Cigarette smoker; N (%) 58 (15) 43 (15) 15 (16) .52
Unknown; N (%) 68 (18) 60 (21) 8 (8)
Alcohol abuser; N (%) 13 (3) 8 (4) 5 (5) .45
Unknown; N (%) 69 (18) 60 (21) 9 (9)
Active drug user; N (%) 2 (0.5) 2 (1) 0 (0) n.a
Unknown; N (%) 87 (22) 51 (18) 36 (35)
Diabetes mellitus; N (%) 80 (21) 56 (21) 24 (24) .56
Unknown; N (%) 20 (5) 19 (7) 1 (1)
Hypertension; N (%) 102 (26) 68 (27) 34 (34) .21
Unknown; N (%) 35 (9) 34 (12) 1 (1)
Dyslipidemia; N (%) 31 (8) 20 (8) 11 (12) .36
Unknown; N (%) 53 (14) 46 (16) 7 (7)
Prior cardiovascular disease; N (%) 83 (21) 54 (21) 29 (29) .14
Unknown; N (%) 34 (9) 33 (12) 1 (1)
Prior peripheral arterial disease; N (%) 28 (7) 22 (9) 6 (6) .38
Unknown; N (%) 36 (9) 35 (9) 1 (1)
Prior cerebrovascular disease; N (%) 25 (6) 13 (5) 12 (12) .02
Unknown; N (%) 32 (8) 31 (11) 1 (1)
Chronic obstructive lung disease; N (%) 48 (12) 36 (14) 12 (12) .64
Unknown; N (%) 29 (7) 27 (9) 2 (2)
Connective tissue disease; N (%) 34 (9) 24 (9) 10 (10) .87
Unknown; N (%) 30 (8) 29 (10) 1 (1)
Chronic liver disease; N (%) 55 (14) 40 (16) 15 (15) .88
Unknown; N (%) 29 (7) 28 (10) 1 (1)
Chronic kidney disease; N (%) 90 (23) 64 (25) 26 (26) .81
Unknown; N (%) 26 (7) 25 (9) 1 (1)
A history of cancer; N (%) 228 (59) 174 (64) 54 (55) .11
Unknown; N (%) 16 (4) 13 (5) 3 (3)
HIV; N (%) 2 (0.5) 2 (1) 0 (0) .37
Unknown; N (%) 35 (9) 33 (12) 2 (2)
Sudden death; N (%) 80 (21) 58 (23) 22 (23) .94
Unknown; N (%) 42 (11) 34 (12) 8 (8)
Autopsy report; N (%) 53 (14) 40 (14) 13 (13) .69
Unknown; N (%) 22 (6) 18 (7) 4 (4)
ABO identical; N (%) 33 (9) 19 (7) 14 (14) .27
Unknown; N (%) 312 (80) 237 (83) 75 (74)
ABO compatible; N (%) 36 (9) 14 (5) 22 (22) <.001
Unknown; N (%) 317 (81) 241 (84) 76 (74)
Functioning graft up to death; N (%) 153 (39) 117 (45) 36 (35) .36
Unknown; N (%) 41 (11) 29 (10) 12 (12)
Graft versus host disease at time of death; N (%) 81 (21) 59 (22) 22 (23) .45
Unknown; N (%) 196 (51) 151 (53) 45 (44)
Complete remission of cancer leading to transplantation; N (%) 75 (19) 61 (23) 14 (14) .20
Unknown/not relevant; N (%) 209 (54) 149 (52) 60 (59)
Concomitant infection; N (%) 212 (55) 145 (74) 67 (68) .05
Unknown; N (%) 112 (29) 89 (31) 23 (23)
Death considered related to treatment; N (%) 15 (4) 10 (4) 5 (5) .79
Unknown; N (%) 68 (18) 63 (22) 5 (5)
The recorded underlying cause of death; N (%) .19
Cancer
∗
133 (34) 96 (34) 37 (36)
Graft rejection/GvHD/failure 120 (31) 88 (31) 32 (31)
Infection 61 (16) 46 (16) 15 (15)
Organ failure or dysfunction 37 (10) 25 (9) 12 (12)
Cardiac or vascular vascular disease 23 (6) 20 (7) 3 (3)
Other causes 2 (0) 2 (1) 0 (0)
Unknown 12 (3) 9 (3) 3 (3)
ABO= (e.g., A, B, O or AB blood groups compatibility), GvHD=Graft versus host disease, HSCT=hematopoietic stem cell transplantation, IQR= Inter-quartile range, n.a=not applicable.
∗
Includes the categories de novo, secondary, relapses, and progression of a known cancer.
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or AB blood groups compatibility) compatibility was higher in
the validation cohort (12% vs 5%, P= .02 and 22% vs 5%,
P< .001, respectively).
Overall, themedian time from transplantation to deathwas 1.3
years (inter-quartile range [IQR] 0.5–3.5). However, this varied
signiﬁcantly between the different types of transplantation; from
40.2 (20.7–69.5) months among kidney recipients to 9.1 months
(1.2–36.8) among liver recipients. The median age at death was
55 years (IQR 42–63) and 58% were men.
Almost all cases were recorded with a speciﬁc code from the list
with pre-deﬁned categories of death (Supplemental digital content
3, http://links.lww.com/MD/C345). The 3 leading recorded
underlying causes of death of the derivation and validation
cohorts were cancer (34% vs 36%), graft versus host disease/graft
rejection/failure (31% vs 31%), and infections (16% vs 15%).
Twelve cases were recorded as “Unknown,” 1 case as “Accident”
and 1 case as “Other causes.” There were no differences in the
recorded underlying cause of death comparing the derivation and
validation cohorts (P= .19) (Table 1). Recorded underlying cause
of death according to transplant type is illustrated in supplemental
digital content 5, http://links.lww.com/MD/C345.
3.2. Comparison of investigator-designated and recorded
underlying cause of death
In the derivation cohort, there was agreement between the
investigator-designated and the recorded underlying cause of
death in 221/286 (77%) (k=0.74 [95% Conﬁdence Interval (CI)
0.69 – 0.80]). Furthermore, the corresponding numbers in the
validation cohort were comparable (80/102 [78%] [k=0.75
[0.66–0.84]]). Best agreement was seen in the derivation cohort
amongst recipients of HSCT, lung, and kidney transplantation
(83%, 82%, and 79%, respectively), compared with liver and
heart transplants (53% and 50%, respectively). This distribution
was generally similar in the validation cohort for all transplant
types except liver transplants (79%, 75%, 85%, 77%, and 50%
for HSCT, lung, kidney, liver, and heart transplants, respectively
(Fig. 2).
In both cohorts, strength of inter-rater agreement was almost
perfect in cases where recorded underlying cause of death was
cancer (k=0.89 [95%CI 0.81–0.97] and k=0.91 [95%CI 0.79–
1.03] in the derivation and validation cohorts, respectively).
Strength of the inter-rater agreement was substantial in the
validation cohort among those recorded as “Infection” or
“Organ failure or dysfunction” whereas agreement in all other
categories was moderate or less in both cohorts (Fig. 3).
In the derivation cohort, characteristics (information retrieved
from the CRF) associated with agreement after adjustment was
“a functioning graft at time of death” and “a history of cancer”
which both led to approximately 3 times higher odds of
agreement compared with those without (adjusted Odds Ratio
[aOR] 2.82 [95% CI 1.37–5.83] and aOR 3.31 [95% CI 1.32–
8.32], respectively). “Cigarette smoking,” “a history of cerebro-
vascular disease,” “a history of liver disease,” and “use of
antibiotics in the month up to death” led to lower odds of
agreement (Table 2).
The characteristics able to signiﬁcantly predict agreement
between the investigator-designated and the recorded underlying
cause of death in multivariate analyses were subsequently
assessed in different combinations, in order to identify patterns
that resulted in the highest agreement in both cohorts. The
combinations of characteristics that led to k >0.70 in both
cohorts are listed in Table 3. For example, Kappa among
recipients with “no history of liver disease” and “no history of
cerebrovascular disease” was 0.78 (0.72–0.84) and 0.74 (0.64–
0.84) in derivation (N=206) and validation (N=75) cohort,
respectively.
3.3. Independent agreement of the recorded underlying
cause of death between external reviewers
Independent agreement of the recorded underlying cause of death
between the 2 external reviewers was obtained in 195 (68%)
cases (k=0.64 [95%CI 0.56–0.69]) in the derivation cohort. The
remaining 91 cases (32%) went through an adjudication process;
which resulted in adjudicated agreement in the majority of these
Figure 2. Proportion of agreement between the investigator-designated cause of death (proposed in CRF) and the recorded underlying cause of death
(determined by the external reviewers after adjudication) according to transplant type. CRF=case record form.
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cases (87/91 [95%]). The remaining 4 cases were sent to an expert
panel for determination of the recorded underlying cause of
death.
In comparison, independent agreement of the recorded
underlying cause of death was obtained in 69/102 (68%) ([k=
0.63 [95% CI 0.52–.73]]) in the validation cohort, whereas the
remaining 33 (32%) were agreed upon during the adjudication
process.
Independent agreement of the recorded underlying cause of
death was generally better among recipients of HSCT and lung
transplantation (77% and 73%, respectively) compared with
kidney, heart, and liver recipients (55%, 50%, 45%, respective-
ly). When considering the derivation and validation cohorts
separately, these proportions remained similar.
In both cohorts, the inter-rater agreement was almost perfect
amongst cases where the recorded underlying cause of death was
cancer (k=0.82 (95%CI 0.72–0.92) and k=0.85 (95%CI 0.70–
1.00) in the derivation and validation cohorts, respectively). For
the remaining recorded underlying cause of death categories, the
inter-rater agreement was fair or slight in both cohorts. An
exception was the “Unknown” category; for this category the
kappa was 1.00 in the validation cohort. However, this group
only consisted of 3 cases.
In the derivation cohort, characteristics (information retrieved
from the CRF) associated with greater odds of independent
agreement of the recorded underlying cause of death between the
2 external reviewers after adjustment was “a history of cancer”
(aOR 3.20 [95% CI 1.45–7.06]); among 174 with this
characteristics, kappa of independent agreement was 0.71
(95% CI 0.64–0.79). These ﬁndings were reproducible in the
validation cohort; among 54 recipients with “a history of
cancer,” kappa was 0.71 (95% CI 0.57–0.84).
3.4. Certainty of the recorded underlying cause of death
The certainty of the recorded underlying cause of death as
determined by the external reviewers after adjudication in the
derivation and validation cohorts was deﬁnite in 70% versus
73%, likely in 26% versus 23%, and possible in 4% versus 4%,
respectively.
Among cases where independent agreement of recorded
underlying cause of death was achieved in the derivation (N=
195) and validation (N=69) cohorts, there was also independent
agreement of the certainty criteria in 71% versus 62%.
3.5. Resources
Two reviewers reported the time consumption of the assessment
process and spent an average of 8minutes to review the CRF and
complete the online Review Form. The assessment process was
completed by all reviewers within 5 and 4 months for the
derivation and validation cohorts, respectively.
3.6. Comparison of recorded underlying cause of death in
this study with the national death cause registry
Comparison between the recorded underlying cause of death
determined in the present study and the cause of death registered
in the DNDCR was possible for 277/286 and 99/102 cases in the
derivation and validation cohorts, respectively. The remaining 12
Figure 3. Agreement (% and Kappa) between investigator-designated cause of death (proposed in CRF) and the recorded underlying cause of death (determined
by the external reviewers after adjudication) according to recorded underlying cause of death in derivation and validation cohort. CRF=case record form.
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deaths had not been ascertained in the DNDCR. Concordance
between the recorded underlying cause of death from our study
and underlying cause of death from the DNDCRwas observed in
37.2% (95% CI 31.5–42.9) and 38.4% (95% CI 28.8–48.0) in
the derivation and validation cohort, respectively (Fig. 4).
When recorded underlying cause of death from the present
study was compared with either immediate, underlying or any
contributing causes of death from the DNDCR, concordance
increased to 62.8% (95% CI 57.1–68.5) and 60.6% (95% CI
50.9–70.3) in the derivation and validation cohorts, respectively.
4. Discussion
We developed and validated a method which was able to
systematically and reliably classify the underlying cause of death
among transplant recipients. The method is ﬂexible and is
tailored to the speciﬁc needs of transplant centers, and can be
applied to any cohort. The only requirement for applying this
classiﬁcation system is access to patient records. The electronic
support structures to handle the process is depicted in Fig. 1 and
all related source documents are available as part of a
collaborative platform on https://www.chip.dk/MATCH. Appli-
cation of this method may facilitate comparison of post-
transplantation mortality in the setting of clinical trials, as well
as allowing evaluation of temporal and regional trends. This is
something that up until now has not been possible to do in a
harmonized and consistent way.
Although this methodology may seem time consuming and
complex, a similar approach has been developed for the reporting
of death in HIV-infected populations, called CoDe.[12,13] The
introduction of CoDe has improved international reporting of the
underlying cause of death and is hence is now the standard
method globally for reporting and classifying death in the HIV
population.[12–14]
We were able to identify speciﬁc patterns that could help select
cases that may not require the assessment of an external reviewer,
since the agreement between the investigator-designated and
recorded underlying cause of death was substantial or almost
Table 2
Odds and Kappa of agreement between the investigator-designated and the recorded underlying cause of death (determined by the
external reviewers after adjudication or an expert panel) in derivation cohort, according to characteristics provided in the case record
form.
Characteristics Univariable OR (95% CI) Multivariable
∗
OR (95% CI) Cohen Kappa (95% CI)
Cigarette smoking
No 1.00 1.00 0.77 (0.70–0.83)
Yes 0.47 (0.23–0.96) 0.36 (0.15–0.86) 0.62 (0.47–0.77)
Unknown 1.59 (0.72–3.50) 1.62 (0.31–8.35) n.a
Excess alcohol consumption
No 1.00 1.00 0.74 (0.68–0.80)
Yes 0.30 (0.07–1.23) 0.24 (0.04–1.54) 0.54 (0.21–0.87)
Unknown 1.33 (0.64–2.74) 0.44 (0.09–1.07) n.a
History of cerebrovascular disease
No 1.00 1.00 0.74 (0.68–0.80)
Yes 0.25 (0.08–0.78) 0.16 (0.04–0.62) 0.46 (0.18–0.74)
Unknown 2.75 (0.80–9.37) 4.79 (0.61–37–78) n.a
History of liver disease
No 1.00 1.00 0.77 (0.71–0.83)
Yes 0.31 (0.15–0.63) 0.22 (0.09–0.58) 0.59 (0.43–0.74)
Unknown 2.11 (0.61–7.30) 0.38 (0.04–3.66) n.a
A history of cancer
No 1.00 1.00 0.58 (0.47–0.69)
Yes 3.25 (1.82–5.79) 3.31 (1.32–8.32) 0.82 (0.75–0.88)
Unknown 7.16 (0.89–57.34) 8.41 (0.48–146.0) n.a
Sudden death
No 1.00 1.00 0.76 (0.70–0.83)
Yes 0.53 (0.28–1.02) 0.53 (0.24–1.17) 0.65 (0.52–0.78)
Unknown 1.21 (0.47–3.13) 0.65 (0.19–2.29) n.a
Functioning graft up to death
No 1.00 1.00 0.67 (0.59–0.75)
Yes 1.83 (1.01–3.33) 2.82 (1.37–5.83) 0.80 (0.72–0.88)
Unknown 2.50 (0.82–7.64) 1.80 (0.46–7.08) n.a
Use of antibiotics in the months up to death
No 1.00 1.00 0.84 (0.73–0.96)
Yes 0.42 (0.17–1.07) 0.31 (0.10–0.97) 0.69 (0.62–0.76)
Unknown 0.91 (0.30–2.71) 0.58 (0.15–2.26) n.a
Transplant type
HSCT 1.00 1.00 0.79 (0.72–0.86)
SOT 0.48 (0.27–0.86) 2.05 (0.72–5.85) 0.68 (0.59–0.76)
No. diagnosis listed in the CRF (per increase of one diagnosis) 0.82 (0.73–0.93) 0.87 (0.74–1.02)
CI= conﬁdence intervals, CRF= case record form, HSCT=hematopoietic stem cell transplantation, n.a=not applicable, OR= odds ratio, SOT= solid organ transplantation.
∗
Inter-rater agreement of the signiﬁcant predictors in in the multivariate model, was almost perfect, for example, no cigarette smoking and no excess alcohol consumption and no cerebrovascular disease and no
chronic liver disease and a history of cancer and a functioning graft up to death and no use of antibiotics up to death (N=8), Cohen Kappa=1.00 (95%CI 1.00–1.00).
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Table 3
Proportion and Kappa of agreement between the investigator-designated and the recorded underlying cause of death (determined by the
external reviewers after adjudication or an expert panel), according to predictors of agreement identiﬁed in the logistic regression
(derivation cohort and validation cohort).
Derivation cohort (N=286) Validation cohort (N=102)
Information in CRF N cases % with agreement Cohen Kappa (95% CI) N cases % with agreement Cohen Kappa (95% CI)
No history of liver disease
AND 179 82 0.79 (0.73–0.85) 77 75 0.71 (0.61–0.82)
No excess alcohol consumption
No history of liver disease
AND 153 82 0.79 (0.72–0.86) 71 76 0.72 (0.61–0.83)
No smoking in the year up to the death
No history of liver disease
AND 206 80 0.78 (0.72–0.84) 75 77 0.74 (0.64–0.84)
No history of cerebrovascular disease
No history of liver disease
AND 143 86 0.82 (0.75–0.89) 49 78 0.73 (0.60–0.86)
A history of cancer
A history of cancer
AND 132 84 0.80 (0.73–0.88) 51 78 0.74 (0.62–0.86)
No excess alcohol consumption
A history of cancer
AND 107 88 0.85 (0.77–0.92) 47 77 0.73 (0.60–0.86)
No smoking in the year up to the death
A history of cancer
AND 152 86 0.82 (0.75–0.89) 49 80 0.76 (0.64–0.88)
No history of cerebrovascular disease
CI= conﬁdence intervals, CRF= case record form.
Figure 4. Agreement between recorded underlying cause of death (determined by the external reviewers after adjudication) in the CLASS project and the Danish
National Death Cause Registry among those where this information was available (N=376) according to recorded underlying cause of death in derivation and
validation cohort.
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perfect. Thus, our results show that using a system where data
were collected in a standardized manner, where the classiﬁcation
algorithm was clearly deﬁned, and where investigators (i.e.,
clinical assistants) were trained in applying this algorithm,
allowed for classiﬁcation of the underlying cause of death in most
cases irrespective of whether specialists or clinical assistants were
responsible for the classiﬁcation. Accordingly, previous studies
have shown that training of participants and standardization of
the classiﬁcation algorithms are of importance when classifying
death causes.[15–18] Thus, we recommend that cases with any
characteristics listed in Table 3 should not be subjected to
external review in future trials. This will reduce the resources
required for application of this method to cohorts markedly.
The agreement varied between the different types of
transplantation, likely reﬂecting the greater diversity of death
causes within the groups with less agreement between the
recorded underlying causes of death. Thus, the likelihood of
coding the underlying cause of death differently is higher if the
course leading to death is more complex and diverse which could
be the case for example in deaths after a liver transplantation.
Our external reviewers independently agreed in 2/3 of the
cases. The remaining cases likely represent the most difﬁcult
cases, and these were either agreed upon during the adjudication
process or by the expert panel. Thus, underlying cause of death
using our methodology was determined through an extensive and
thorough system including assessment that involved several
experts.
Conversely, we found a high degree of discordance between the
recorded underlying causes of death as determined by our
experts, and those listed in the DNDCR. It is important to note
that this was a comparison of individual data and not aggregated
data, and that<40% of the cases were concordant. The DNDCR
are based on death certiﬁcates ﬁlled out by clinicians. In Denmark
it is usually the youngest physician that is responsible for this.
However, junior physicians may not have the necessary clinical
expertise within transplant medicine to be able to determine cause
of death in such a specialized setting. Furthermore, previous
studies have reported signiﬁcant errors associated with the
completion of the death certiﬁcates[15,19,20] which is likely to also
lead to errors in the determination of the underlying cause of
death. In addition, autopsy reports are rarely available at time the
death certiﬁcates are ﬁlled out, yet these reports may contribute to
a more precise classiﬁcation.[20,21] In our methodology, all
available autopsy reports were part of the assessment process.
Thus, the key question that is raised by the present study is
whether the DNDCR can be used for classiﬁcation of death in the
setting of transplantation.
Conversely, reports on causes of death in transplant recipients
in the literature are often based on national transplant
registries.[3,19,22–25] However, causes of death in these registries
are often obtained on death notiﬁcation forms similar to the
DNDCR.
While neither the methodology proposed here nor the different
registries mentioned above can be considered the golden
standard, we consider our method to be more accurate in the
transplant setting. Our method involves several steps in order to
get as close to the true cause of death as possible, including
speciﬁc training of all participants, a standardized algorithm to
determine the cause of death, and independent assessment and
adjudication by specialists in case of disagreement.
Importantly, our classiﬁcation system has 3 levels of certainty
(possible, likely and deﬁnite cause of death) and aims to reduce
the number of unknown categories. We prefer to try and
anticipate a high number of cases and make use of the lower
degrees of certainty, rather than having a large pool of patients
who died from unknown causes. Accordingly, only 12/388 (3%)
of the underlying cause of death was recorded as “Unknown.”
The 3 levels of certainty also allows for sensitivity analysis of
outcomes in recipients where likely and possible causes could be
included or excluded, in order to test the robustness of the
observations.
Our results should be seen in the light of their limitations. We
acknowledge that our method relies on the accuracy and the
degree of detail of the patient records; the more accurate
information available, the more likely it is that we were able to
determine the underlying cause of death accurately. Furthermore,
this methodology may be time-consuming, although the above
suggested recommendations can reduce resources signiﬁcantly.
In summary, this is the ﬁrst validated method to reliably
classify underlying causes of death in transplant recipients. We
believe that this methodology may facilitate the detection
potential emerging health-threatening challenges within this
vulnerable population of patients, by providing more granular
and accurate information on the underlying cause of death.
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